PRESIDENT'S MESSAGE

Learn More About PMSA Programs in Our New Videos


PMSA has unveiled two brand new videos highlighting the association's educational offerings, and the benefits of partnering with PMSA as a sponsor at our Annual Conference.

Our first new video focuses on PMSA in-person events and our other educational resources. PMSA events are a great way to keep tabs on innovation in the pharma analytics industry and network with colleagues. Watch the short video below for a wrap-up of the 2018 PMSA Annual Conference, and learn about our webinar program, PMSA Journal, and other opportunities!
Vendors wishing to partner with PMSA as a sponsor at our Annual Conference can reach top decision-makers in pharma data analytics. Watch the video below to hear from past sponsors of PMSA on the benefits of PMSA Conference sponsorship. 
If you spot a colleague in the above videos, be sure to share with them via social media!

Jin Tong
President, PMSA

Artificial intelligence and machine learning are being hailed as the future of data analytics. Computer models can analyze high volumes of real-time data to make more accurate market predictions. How are these powerful tools currently being leveraged by pharma data scientists, and what does the future hold for AI in the pharma industry?

PMSA is seeking presenters to help design a training seminar for our Winter Symposium in 2019. Thought leaders and consulting companies are being asked to help with this important and well-attended conference; only a few will be selected to speak, and only one company will be selected for the hands-on training workshop.

The 2019 PMSA Winter Symposium will address, but not be limited to, the following questions:
  • What impact will AI have on behavioral science?
  • How can natural language processing improve pharma analytics projections?
  • How can next best action be used to more accurately predict the patient journey?
  • What are the best methods to analyze payer analytics and market access via machine learning?
  • How will AI improve the accuracy of rare disease analytics?
  • How should the analytics focus change with the product life cycle?
  • What are the best patient co-pay assistance strategies, and how can AI be leveraged to find better rebates and co-pay offerings to generate the most profitable mix?
Submission deadline for RFP Application: Monday, October 8, 2018
Authors will be contacted by: Monday, October 22, 2018
Send proposals to Brian Doty at bdoty@pmsa.net

Click here to download the Call for Proposals [PDF] 

    2018 European Summit Wrap Up

    In early September, PMSA once again convened in Europe for its 2018 European Summit. Forty pharmaceutical analytics professionals gathered at the Hilton Amsterdam to discuss:
    • Machine Learning
    • GDPR
    • Measuring Customer Engagement
    • Clinical Practice Research Datalink
    • Medical Affairs
    PMSA Members: Visit pmsa.net/past-symposia-presentations to access presentations from the 2018 European Summit.

    MEMBER SPOTLIGHT

    PMSA Member Spotlight: Tatiana Sorokina, Novartis


    Each edition of PMSA Notes will include a spotlight on a noteworthy PMSA member. This month's spotlight focuses on Tatiana Sorokina, Associate Director, Digital & Advanced Analytics, Novartis, who is currently serving as a member of the PMSA Marketing Committee. 

    Tatiana leads Advanced Analytics for Oncology at Novartis and is focused on building scalable technology and driving automation in marketing. Tatiana has been developing machine learning and artificial intelligence solutions for the healthcare industry for more than 5 years. Prior to joining Novartis, she has run Parceed, an AI-based guidance system for medical students. Before starting her own company, Tatiana was a Head of Data Science at Prognos, a healthcare technology company that applies AI to clinical lab diagnostics. Tatiana holds M.Sc. in Advanced Analytics in Marketing from Columbia University and B.Sc. in Economics from Moscow State University. She blogs about data science and entrepreneurship at www.insightmine.com
    PMSA: What attracted you to the field?
    Tatiana: I have always wanted to be in a field that is ripe for innovation. I felt like this would be a great opportunity for me to make a change for the better. That said, I wanted to make a change in the field that could have the biggest impact on people. Healthcare concerns every one of us, and innovation applied in healthcare may lead to big improvements in longevity and quality of life. I am humbled by the thought that I can contribute to this improvement.

    Click here to read the interview

    SPONSOR SPOTLIGHT

    PMSA Sponsor Spotlight: Panel Analysis - Optimizing Predictive Analytics for Improved Commercialization


    Businesses are thirsty for a competitive edge. Harnessing the power of predictive analytics in bringing medicines to market can provide valuable insights to drive that advantage, and when put into practice, can have far reaching implications to the future of life sciences. Predictive analytics in the life sciences industry has long struggled to cope
    with the challenges of identifying and decoding the complexity of human behavior and its changes over time; however, if used correctly today, it can help optimize commercialization with planning, production, and distribution.

    The basis of a valuable predictive analysis lies in its handling of seemingly “unexplainable” events – events whose impact on the desired response is difficult to estimate and extract. For example, when trying to estimate the impact of field calls on product sales, it is important to understand and extract the impact of unexplainable environmental
    factors such as political events, market trends, seasonal trends, etc. away from the desired impact of field calls. In order to discover the true patterns of such underlying opportunities as Rx trend or behavior, one must remove or minimize as much as possible the impact these unexplainable events have on the analysis, keeping in mind the
    primary measurement of success for predictive analytics is how well it reflects reality.
    From a life sciences commercialization perspective, promotion response has been a chronic victim of these persistent unexplainable events inadvertently influencing the
    desired response. Proper modeling with panel analysis can largely alleviate any undesired impact and yield a more accurate promotion response.

    2018 PMSA Sponsors

    PMSA Board of Directors

    Jin Tong, Novartis
    President

    Karthikeyan Chidambaram, Genentech
    Vice President

    Vishal Chaudhary, Sanofi
    Treasurer/Secretary

    Nuray Yurt, Novartis
    Professional Development Chair

    Igor Rudychev, Pfizer
    Research and Education Chair

    Haibei Jiang, Bayer Pharmaceuticals
    Marketing Chair 
     
    Arlene Little, Genentech 
    Program Committee Lead
     
    Nathan Wang, Janssen Pharmaceuticals
    Program Committee

    Mehul Shah, Sanofi
    Program Committee

    David Purdie, Genentech
    Executive Advisory Council

    Cynthia Dilley, UCB
    Executive Advisory Council

    Jason Carlin, Novartis
    Executive Advisory Council

    If you are employed by a pharmaceutical or biotech manufacturer and are interested in joining the board in the future, please reach out to us to let us know! Contact Chris Walls at cwalls@pmsa.net. We’ll keep you in mind for the next possible opportunity.

    PMSA Notes Editor:
    Haibei Jiang, Marketing Chair